NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase
a

Compound: Mucronulatol

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
CCNE1cyclin E1898Colorectal AdenocarcinomaHCT-8----Cyclin E was down-regulated in a concentration-dependent manner.18538108
CDK4cyclin-dependent kinase 41019Colorectal AdenocarcinomaHCT-8----CDK4 was down-regulated in a concentration-dependent manner.18538108
CDKN1Acyclin-dependent kinase inhibitor 1A (p21, Cip1)1026Colorectal AdenocarcinomaHCT-8----Increasing concentrations of mucronulatol induced an up-regulation of both p21Cip1 protein level.Increment in p21Cip1/p27Kip1 protein levels, inhibiting the physiological functions of the cyclin E/CDK2 complex.18538108
CDKN1Bcyclin-dependent kinase inhibitor 1B (p27, Kip1)1027Colorectal AdenocarcinomaHCT-8----Increasing concentrations of mucronulatol induced an up-regulation of both p27kip1 protein level.Increment in p21Cip1/p27Kip1 protein levels, inhibiting the physiological functions of the cyclin E/CDK2 complex.18538108
TOP2Atopoisomerase (DNA) II alpha 170kDa7153Colorectal AdenocarcinomaHCT-8----We observed a presumptive compensatory effect in the expression of topoisomerase II-alpha, which is up-regulated.It appears that the gene expression of topoisomerase II-alpha remained unaltered, whereas its protein levels suffered an increase in a drug concentration-dependent manne.18538108
TOP2Btopoisomerase (DNA) II beta 180kDa7155Colorectal AdenocarcinomaHCT-8----Topoisomerase II-Beta protein levels were found decreased upon drug administration, an effect which seemed to be slightly compensated for by increased gene expression.18538108

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.